COMMUNIQUÉS West-GlobeNewswire

Scorpius Holdings Achieves 16% Year-Over-Year Increase in Revenue for the Second Quarter of 2024
20/08/2024
Reduces operating expenses by 25% Pipeline surpasses $100 million in weighted opportunities across the government and manufacturing sectors DURHAM, N.C., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE [...]
Orion Corporation: Managers’ transactions – Liisa Hurme
20/08/2024
ORION CORPORATION MANAGERS’ TRANSACTIONS 20 AUGUST 2024 at 16.15 EEST Orion Corporation: Managers’ transactions – Liisa Hurme Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Legend Senior Living® Assumes Management of Crescent Fields Senior Living Community in Huntingdon Valley, Growing Portfolio to 60
20/08/2024
HUNTINGDON VALLEY, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Legend Senior Living, with headquarters in Wichita, KS, has entered into a management agreement with the owners of Crescent Fields at Huntingdon Valley to [...]
Carilion Clinic further expands quality cardiac care access with latest Philips innovations at new regional cardiovascular institute in Virginia, US
20/08/2024
August 20, 2024 Integrated Philips cardiovascular solutions enhance the patient & staff experience with reduced X-ray dose & procedure time for more time with patients and to help improve outcomes New facility [...]
Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024
20/08/2024
CHICAGO and FORT WORTH, Texas, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for [...]
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
20/08/2024
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new [...]
TerrAscend Announces $10 Million Share Repurchase Program
20/08/2024
TORONTO, Aug. 20, 2024 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF) , a leading North American cannabis company, today announced that its Board of Directors has [...]
Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak
20/08/2024
Roche is committed to supporting all those working to overcome the mpox outbreak by providing access to high-quality Polymerase Chain Reaction (PCR) testing Roche confirms that its cobas MPXV test, as well as the [...]
SI-BONE, Inc. Receives 510(k) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System
20/08/2024
SANTA CLARA, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, announces FDA 510( [...]
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
20/08/2024
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Additional commentary published discussing the potential of Ampligen and two other drugs OCALA, Fla [...]
NeuroStar® Marks Two Years of Transformative Impact with NeuroStar University
20/08/2024
Celebrating milestones in patient care and practice enhancement through NeuroStar’s innovative training facility MALVERN, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology [...]
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
20/08/2024
CORAL GABLES, Fla., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and [...]
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung
20/08/2024
NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the appointment of Winston Kung to its Board of Directors. The [...]
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
20/08/2024
SOMERSET, N.J., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive [...]
Nanox Announces Second Quarter of 2024 Financial Results and Provides Business Update
20/08/2024
Accelerated the deployment of Nanox ARC in the US market, Submitted a new 510k application to the FDA to expand Nanox.ARC indications to include general use, including chest Nanox.AI Receives FDA 510K Clearance for [...]
Entera Bio to Participate in Upcoming Investor and Scientific Conferences
20/08/2024
JERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that [...]
Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024
20/08/2024
Media Release Oral presentation will detail results from the randomized TACTI-003 Phase IIb trial in first line head & neck squamous cell carcinoma patients with any PD-L1 expression (CPS > 1) SYDNEY, AUSTRALIA, [...]
Avadel Pharmaceuticals Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension
20/08/2024
DUBLIN, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of results of a post [...]
Opus Genetics Receives Rare Pediatric Disease Designation from the U.S. FDA for Ocular Gene Therapy OPGx-LCA5 to Treat Rare Inherited Retinal Disease LCA5
20/08/2024
Priority Review Voucher would be issued upon approval of OPGx-LCA5 RESEARCH TRIANGLE PARK, N.C., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first, clinical-stage gene therapy company developing [...]

Pages